Arbutus Biopharma Corp.,a two-year-extinct biopharmaceutical company attempting to develop a cure for hepatitis B infections, won the latest round in its ongoing dispute over a cross licensing deal it made with a Canadian drug company.
This week the Supreme Court of British Columbia granted a request by Arbutus (NASDAQ: ABUS)— which has offices in Vancouver and Doylestown, and Pennsylvania — for a pre-trial injunction preventing Acuitas from sublicensing Arbutus’ lipid nanoparticle [LNP] technology…
Source: bizjournals.com